NIMBLE Diagnostics Closed Funding of Over 1 million Euros


Awarded 1.000.000 Euros

NIMBLE Diagnostics’ funding has shown immense success. NIMBLE Diagnostics has successfully closed a funding round led by Grow Venture Partners together with Namarel Ventures and Inveniam Group. They have secured over 1 million euros to continue their mission of saving lives through preventative care.

NIMBLE Diagnostics is a spin-off company of experts in the cardiology field of Germans Trias i Pujol Research Institute (IGTP), the Universitat Politècnica de Catalunya (UPC) – BarcelonaTech and the Universitat de Barcelona. They are all working together to create a medical technology device, the first of its kind, to monitor patients with implanted stents to detect life-threatening complications before they create irreversible damage.

«This capital will allow NIMBLE Diagnostics to finish preclinical testing, consolidate the team, conduct regulatory studies and carry out the first clinical trial at the Hospital Universitari Germans Trias i Pujol in 2024.»

Oriol Iborra Egea, PhD, IGTP researcher and CEO